EUVIMEDEUVIMED entdecken
Crossref

Real-World Treatment Patterns and Outcomes Among Patients With Newly Diagnosed AML in the United States

Elizabeth Dianne Pulte iD, Laura L Fernandes, Kelly Norsworthy iD, Joseph Wynne iD, Eric Hansen, Andrew J Belli, Anna Barcellos iD, Christina M Zettler iD, Rebecca Bystrom iD, Jonathon Vallejo iD, Catherine Lerro, Ching-Kun Wang iD und 2 weitere

JCO Oncology Practice · 30.04.2026

DOI: 10.1200/op-25-00885 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, online erschienen am 30.04.2026. Verfasst von Elizabeth Dianne Pulte und 13 weiteren Autor:innen. Beteiligte Einrichtung: Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The US Food and Drug Administration has approved multiple new treatments for AML since 2017 based on demonstrated efficacy and safety in clinical trials. However, the uptake of new treatments and effectiveness in the routine clinical practice are largely unknown. METHODS A retrospective observational study was conducted to examine first-line therapy in patients with AML who were treated at institutions providing data to the COTA database. Information on demographics, disease characteristics, treatments, and outcomes was collected and analyzed descriptively. RESULTS Among the 2,516 patients eligible for inclusion in our analysis, cytarabine-based intensive chemotherapy (IC w/cytara) was the most commonly used treatment, followed by hypomethylating agents (HMA) with venetoclax (HMA+ven), HMA alone, and investigational treatment. Use of HMA+ven increased over time since its approval in 2018, whereas use of IC w/cytara and HMA alone decreased. Complete remission rates were 45% overall and highest in patients treated with IC w/cytara (61%) or investigational therapy (62%). CONCLUSION Overall survival was highest for patients treated with IC w/cytara, although differences in baseline patient characteristics make direct comparison infeasible. Uptake of HMA+ven as a first-line treatment for patients with AML has been more rapid compared with other newly approved therapies. Outcomes for patients treated in routine practice were similar to those seen in clinical trials. Further research may be helpful in characterizing real-world effectiveness and safety in specific subpopulations and disease subtypes.

Autor:innen und Institutionen

  • Office of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
  • COTA, Inc, New York, NY.
  • National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
  • Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD.

ORCID-Profile: Elizabeth Dianne Pulte, Kelly Norsworthy, Joseph Wynne, Anna Barcellos, Christina M Zettler, Rebecca Bystrom, Jonathon Vallejo, Ching-Kun Wang, Donna Rivera, Angelo de Claro

Zitieren

APA

Pulte, E. D., Fernandes, L. L., Norsworthy, K., Wynne, J., Hansen, E., Belli, A. J., Barcellos, A., Zettler, C. M., Bystrom, R., Vallejo, J., Lerro, C., Wang, C. K., Rivera, D., & de Claro, A. (2026). Real-World Treatment Patterns and Outcomes Among Patients With Newly Diagnosed AML in the United States. JCO Oncology Practice. https://doi.org/10.1200/op-25-00885

Vancouver

Pulte ED, Fernandes LL, Norsworthy K, Wynne J, Hansen E, Belli AJ, et al. Real-World Treatment Patterns and Outcomes Among Patients With Newly Diagnosed AML in the United States. JCO Oncology Practice. 2026. doi:10.1200/op-25-00885

BibTeX
@article{Pulte2026,
  author = {Pulte, Elizabeth Dianne and Fernandes, Laura L and Norsworthy, Kelly and Wynne, Joseph and Hansen, Eric and Belli, Andrew J and Barcellos, Anna and Zettler, Christina M and Bystrom, Rebecca and Vallejo, Jonathon and Lerro, Catherine and Wang, Ching-Kun and Rivera, Donna and de Claro, Angelo},
  title = {Real-World Treatment Patterns and Outcomes Among Patients With Newly Diagnosed AML in the United States},
  journal = {JCO Oncology Practice},
  year = {2026},
  doi = {10.1200/op-25-00885}
}
Kostenlos starten →